hec53856
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 14, 2019 (NCT03886688)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
SETD2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04925661 | Phase 1 | Sep 29, 2021 | Government of China, Sunshine Lake Pharma Co., Ltd. |
| NCT04925674 | Phase 1 | Sep 29, 2021 | Government of China, Sunshine Lake Pharma Co., Ltd. |
| NCT03886688 | Phase 1 | May 14, 2019 | Jilin University, Sunshine Lake Pharma Co., Ltd. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sunshine Lake Pharma Co., Ltd. | For profit | 3 | 3 | 1 | 2019 |
| Government of China | Government | 2 | 0 | 1 | 2021 |
| Jilin University | Academic/Hospital | 1 | 0 | 1 | 2019 |
3 organizations
Page 1 / 1